KCM
SION

Kennedy Capital Management’s Sionna Therapeutics SION Stock Holding History

Kennedy Capital Management’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$492K Buy
12,284
+5,532
+82% +$211K 0.01% 515
2025
Q4 		$278K Buy
+6,752
New +$256K 0.01% 520

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Kennedy Capital Management's SION Position: Q1 2026 in Review

Kennedy Capital Management increased its Sionna Therapeutics (SION) stake by 82% in Q1 2026, buying an estimated $211K and bringing the position to 12,284 shares worth $492K. The position accounts for 0.01% of the portfolio, ranked #515.

Kennedy Capital Management first reported a position in SION in Q4 2025 and has held it in 2 quarters since. 122 funds tracked by Wall St. Rank hold SION as of Q1 2026.

  • Kennedy Capital Management held 12,284 shares of Sionna Therapeutics worth $492K as of Q1 2026.
  • Kennedy Capital Management bought 5,532 Sionna Therapeutics shares in Q1 2026, an estimated $211K.
  • Sionna Therapeutics made up 0.01% of Kennedy Capital Management's portfolio in Q1 2026, its #515 holding.
  • Kennedy Capital Management first reported a position in Sionna Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 122 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q1 2026.

Based on Kennedy Capital Management's 13F filing for Q1 2026, filed 13 May 2026.